Defective CD24^hiCD27⁺ B-cell and enriched plasmablast B-cell pools in cGVHD patients. (A) Percentages of CD19⁺ cells in proportion to live lymphocytes in AHSCT recipients with no GVHD, patients with active cGVHD, patients with cGVHD in remission, and healthy donors. (B) Dot plots of the expression of CD24 and CD27 by live CD19⁺ cells in a representative healthy donor, patient with no GVHD, and with cGVHD (left panel). Proportions of CD24^hiCD27⁺ B cells in live CD19⁺ cells from allogeneic recipients with no GVHD, patients with active cGVHD, patients with cGVHD in remission, and healthy donors (right panel). (C) Dot plots of the expression of CD24 and CD38 by live CD19⁺ cells in a representative healthy donor, patient with no GVHD, and with cGVHD (left panel). Proportions of CD24⁻CD38^hi B cells in live CD19⁺ cells from AHSCT recipients with no GVHD, patients with active cGVHD, patients with cGVHD in remission, and healthy donors (right panel). (D) Proportions of CD24⁻CD38^hi B cells in live CD19⁺ cells from patients with cGVHD (active or in remission) according to the presence or absence of ANAs (titer ≥1/80).